The Conundrum of Exercise for Weight Management in the GLP-1 Receptor Agonist Era
Authors:
Top Cited Papers
- 2 June 2026
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 335 (21) , 1841
Abstract
This Perspective describes the challenges of prescribing exercise for weight loss, with and without the use of glucagon-like peptide 1 (GLP-1) receptor agonists, and discusses strategies clinicians can use to improve adherence to exercise recommendations.Keywords
This publication has 23 references indexed in Scilit:
- Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and JapanJAMA Cardiology, 2025
- Discontinuation of Glucagon-Like Peptide-1 Receptor AgonistsJAMA, 2025
- GLP1Ra‐based therapies and DXA‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trialsObesity, 2024
- Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needsObesity Pillars, 2024
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both CombinedNew England Journal of Medicine, 2021
- Exercise adaptations: molecular mechanisms and potential targets for therapeutic benefitNature Reviews Endocrinology, 2020
- Correlates of physical activity: why are some people physically active and others not?The Lancet, 2012
- Effect of an Intensive Exercise Intervention Strategy on Modifiable Cardiovascular Risk Factors in Subjects With Type 2 Diabetes MellitusA Randomized Controlled Trial: The Italian Diabetes and Exercise Study (IDES)Intensive Exercise and Modifiable CV Risk FactorsArchives of internal medicine (1960), 2010
- Physical Activity and Weight Gain PreventionJAMA, 2010
- How much physical activity is needed to minimize weight gain in previously obese women?The American Journal of Clinical Nutrition, 1997